Trim 33-50% via thirds into $159-164 supply zone; preserve 50-67% residual for Q4 FY26 print optionality
Underweight is the calibrated response: three consecutive Holds at this setup type have produced -3.5% cumulative alpha (breaching the alpha-cost ceiling), the 8/24 dense-bearish-convergence lesson explicitly overrides passive neutrality at elevated valuations (21.8x forward P/E), and the catalyst stack (Jackson Hole, Q4 print) is concentrated within 24-72 hours. Full Sell forfeits Q4 print optionality and has been empirically penalized (8/20 +1.2% opportunity cost, 8/25 -2.1% direct alpha loss). The measured trim-and-preserve strategy honors both the structural floor (intact $3.71B FCF, 67-year dividend streak, Equinor/BP contracts) and the documented alpha-cost ceiling.
| Position | Action |
|---|---|
| Rally to $159-160 | Reduce 1/3 of position |
| Rally to $161-162 | Reduce 1/3 of position |
| Rally to $163-164 | Reduce final 1/3 of position |
| Price above $164.50 | Hard abort - do not execute additional reduction |
| Position retained after trim | Maintain 50-67% residual to participate in Q4 FY26 print optionality |
EMR is a structural uptrend within a healthy consolidation phase, not a reversal, supported by forward EPS of $7.24 (58% above trailing), a 0.37 PEG ratio, and material backlog-building catalysts including Equinor's 13-year global standardization agreement and BP's Shah Deniz contract.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 148.48 | bullish |
| close_200_sma | 141.05 | bullish |
| close_10_ema | 157.63 | neutral |
| macd | 2.61 | bearish |
| macds | 3.56 | bearish |
| macdh | -0.95 | bearish |
| rsi | 55.3 | neutral |
| boll | 158.40 | neutral |
| boll_ub | 165.82 | neutral |
| boll_lb | 150.98 | neutral |
| atr | 3.93 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close above $164.30 on volume >3M with MACD bullish cross
Then: Re-engage/add to position on breakout confirmation
Forward EPS of $7.24 represents 58% earnings expansion and is not fairly valued at current levels
↩ rebuts: “Simply Wall St.'s 'fairly valued' label based on trailing $4.57 EPS”
EV: +15% (to $181 at 25x forward P/E on $7.24 EPS); Target $170+ on breakout · concedes: MACD crossed bearish, RSI cooled from 72.5 to 55, price sitting below Bollinger mid-band and VWMA — acknowledged but framed as normal consolidation, not reversal; Five-million-share days on Aug 4–5 at highs could be distribution (not just institutional accumulation); Q2 FY26 revenue print of -1.9% is acknowledged as weak; 88% odds of no Fed cuts means higher-for-longer rates are mild valuation headwind; Goodwill of $27B and $11.57B net debt are costs of building the future earnings stream
EMR is a stock where the price has already absorbed every piece of good news, and the asymmetry is no longer in the buyer's favor — the EPS recovery is accounting-driven (amortization roll-off) not operational, revenue growth is flat-to-down, and the stock trades at a 70% premium to its sector at peak optimism.
EV: -$130 (18x × $7.24) to $115 (downside 17–27%) · concedes: EMR is not a broken company; Equinor 13-year frame agreement and BP Shah Deniz are genuinely good business wins; The long-term trend is up; Revenue from the NI acquisition adds to the top line mechanically
→ vs neutral: HOLD position is 'paralysis' and 'coward's compromise' equivalent to 'watching a building on fire and keeping your appointment across the street'; the 200 SMA at $141 is a destination, not a floor; 'structurally bullish long-term uptrend' is irrelevant when distribution days are occurring at August highs with 5+ million shares on the way up
→ vs conservative: The conservative trailing stop at $148-150 is not risk management but capitulation; should be 'even more aggressive about reducing exposure' because the cost of being wrong on the long side is 'asymmetrically larger than the cost of being wrong on the short side'; waiting for 'confirmation' is wrong when Jackson Hole is tomorrow and Q4 FY26 print is right behind it
| vwma | 159.41 | bearish |
Support: — | Resistance: —
EMR shows strong long-term bullish structure (price above all MAs, rising 200 SMA) but short-term momentum is bearish (MACD crossover, negative expanding histogram, RSI cooling from 72.5 overbought to 55.3). Price consolidation in $154–$164 range with current close $157.71 sitting below VWMA ($159.41) and Bollinger mid-band ($158.40). Support levels: S1 $154.96, S2 $150.98, S3 $148.48 (50 SMA critical). Resistance: R1 $163.86, R2 $164.31, R3 $165.82. Recommended action: HOLD for existing positions with trailing stop near $148–$150; new entries wait for pullback to $154–$156 or breakout above $165.82.
Market Capitalization
$87.97B
P/E (TTM)
34.51x
Forward P/E
21.79x
PEG Ratio
1.79
Price / Book
4.32x
Revenue (TTM)
$18.64B
Revenue FY2025
$18.02B
Revenue FY2024
$17.49B
Gross Margin (TTM)
53.2%
Operating Margin (TTM)
26.9%
Profit Margin (TTM)
13.8%
EBITDA (TTM)
$6.06B
ROE
12.8%
ROA
6.9%
EPS TTM
$4.57
Forward EPS
$7.24
EPS FY2025
$4.04
Normalized Net Income FY2025
$2.62B
Restructuring Charges FY2025
$442M
Amortization FY2025
$1.52B
Total Assets (Jun'26)
$42.09B
Total Equity
$20.30B
Total Debt (Latest Q, Jun'26)
$14.06B
Net Debt
$11.57B
Cash & Equivalents
$1.79B
Goodwill + Intangibles
$27.11B
Tangible Book Value
-$7.37B
Working Capital
-$1.40B
Current Ratio
0.90
Operating Cash Flow FY2025
$3.10B
Free Cash Flow (TTM)
$3.71B
FCF Conversion
>140%
CapEx FY2025
$431M
Dividend Payments FY2025
$1.19B
Buybacks FY2025
$1.17B
Quarterly Dividend
$0.555
Dividend Yield
1.40%
Beta
1.235
52-Week High
$166.35
52-Week Low
$122.64
50-Day MA
$148.70
200-Day MA
$141.91
Q2 FY26 Revenue YoY
-1.9%
Q3 FY26 Revenue YoY
+0.2%
Strengths
Concerns
Emerson Electric is transitioning from a diversified conglomerate to a focused automation specialist following the Climate Technologies divestiture and National Instruments acquisition, with strong fundamentals including 53.2% gross margins, >140% FCF conversion, and an EPS doubling thesis as restructuring charges and amortization roll off over the next 12-18 months. However, the stock trades at a premium 34.5x TTM P/E despite negative tangible book value, elevated leverage (~3.1x), and moderating revenue growth (+3% TTM) that raises questions about the pace of the industrial automation cycle recovery. The primary investment thesis centers on the forward P/E of 21.8x and expected EPS recovery to $7.24, offering ~15% upside potential at a 25x multiple if the company executes on integration synergies.
Macro: Fed policy is in a hawkish hold mode with an 88% probability of no rate cuts in 2026 based on Polymarket data ($7.58M traded, +2.2pp over the past week), with Fed Chair Warsh's Jackson Hole speech scheduled for Aug 28, 2026. Soft-landing consensus dominates with US recession probability priced at just 8% by YE2026 ($1.72M), UK at 11%, and Japan at 20% (falling sharply -10.5pp weekly). Energy crosscurrents include Venezuela weighing an OPEC exit (potential 0.5–1.0mbpd supply addition) which could pressure upstream capex, though IOC capex discipline appears intact based on EMR's recent contract wins. Institutional rotation is active into quality industrials with EMR featured on Kiplinger and StockStory buy lists, while defensives like Walmart show leadership erosion (-10% monthly). Data-center power demand remains a structural theme driving automation, instrumentation, and thermal management orders.